PEDRO PIEDRA to Nanoparticles
This is a "connection" page, showing publications PEDRO PIEDRA has written about Nanoparticles.
Connection Strength
0.964
-
Profile of respiratory syncytial virus prefusogenic fusion protein nanoparticle vaccine. Expert Rev Vaccines. 2021 04; 20(4):351-364.
Score: 0.598
-
A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. J Infect Dis. 2016 Feb 01; 213(3):411-22.
Score: 0.100
-
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2013 Jan 07; 31(3):524-32.
Score: 0.083
-
Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV (respiratory syncytial virus) replication in cotton rats. Vaccine. 2025 May 22; 56:127183.
Score: 0.049
-
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020 12 10; 383(24):2320-2332.
Score: 0.036
-
Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. N Engl J Med. 2020 07 30; 383(5):426-439.
Score: 0.035
-
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Vaccine. 2018 12 18; 36(52):8069-8078.
Score: 0.031
-
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018 10; 18(10):e295-e311.
Score: 0.031